New therapeutic approach to Toxic Epidermal Necrolysis (TEN) using anti-CD38+ antibodies in the active phase of the disease – Phase I/II study to assess the tolerance and efficacy of DARATUMUMAB - NET-CD38 Study
Phase 1/2
Not yet recruiting
- Conditions
- Toxic Epidermal Necrolysis
- Registration Number
- 2024-512164-63-00
- Lead Sponsor
- Hospices Civils De Lyon
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised, recruitment pending
- Sex
- Not specified
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospices Civils De Lyon
🇫🇷Pierre Benite, France
Hospices Civils De Lyon🇫🇷Pierre Benite, FranceBenoit BEN SAIDSite contact+33472117211benoit.ben-said@chu-lyon.frFlorence HACARDSite contact33478864125florence.hacard@chu-lyon.fr